非侵襲的出生前検査市場- 世界の産業規模、シェア、動向、機会、予測、製品タイプ別、検査方法別、用途別、エンドユーザー別、地域別、競合別、2020-2030F

非侵襲的出生前検査（NIPT）の世界市場は、2024年に50億3,000万米ドルと評価され、2030年には77億4,000万米ドルに達すると予測され、予測期間中のCAGRは7.42％で成長します。

この成長の原動力は、遺伝性疾患に対する意識の高まりと、より安全で非侵襲的な出生前スクリーニングの代替手段に対する需要です。母親の年齢が世界的に上昇し続けるにつれ、染色体異常のリスクも上昇し、好ましいスクリーニングの選択肢としてNIPTの採用が広がっています。この技術は、母体からの簡単な血液サンプルを用いて正確な結果を提供し、羊水穿刺のような侵襲的な処置に伴うリスクを排除します。早期診断イニシアチブに対する政府の支援、民間ヘルスケアへのアクセスの進歩、迅速な結果の利便性が市場をさらに強化しています。さらに、AIベースの分析やマルチプレックスアッセイ開発などの技術革新がNIPTの範囲と精度を拡大する一方、在宅検査ソリューションに対する消費者の需要が、より患者中心の医療提供モデルを再構築しています。

市場促進要因

母体年齢の上昇とそれに伴う染色体異常リスク

主な市場課題

NIPTの限界

主要市場動向

消費者直接検査の利用可能性

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界非侵襲的出生前検査（NIPT）市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 製品タイプ別（消耗品、機器）
  • 検査種別（Materni 21、Harmony、Panaroma、Verifi、NIFTY、その他）
  • 方法別（超音波検査、生化学スクリーニング検査、細胞遊離DNA母体血漿検査、母体血液中の胎児細胞検査、その他）
  • 用途別（トリソミー、微小欠失症候群、その他）
  • エンドユーザー別（診断研究所、病院、その他）
  • 地域別
  • 企業別（2024）
• 市場マップ

第6章 北米非侵襲的出生前検査（NIPT）市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • カナダ
  • メキシコ

第7章 欧州非侵襲的出生前検査（NIPT）市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • ドイツ
  • 英国
  • イタリア
  • フランス
  • スペイン

第8章 アジア太平洋非侵襲的出生前検査（NIPT）市場展望

• 市場規模・予測
• 市場シェア・予測
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • 日本
  • 韓国
  • オーストラリア

第9章 南米非侵襲的出生前検査（NIPT）市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東およびアフリカ非侵襲的出生前検査（NIPT）市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 最近の動向
• 合併と買収
• 製品上市

第13章 世界非侵襲的出生前検査（NIPT）市場： SWOT分析

第14章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第15章 競合情勢

• YOURGENE HEALTH Plc
• Illumina, Inc.
• Natera, Inc.
• F.Hoffman La Roche Ltd.
• Perkin Elmer Inc.
• Laboratory Corporation of America Holdings
• Eurofins LifeCodex GmbH
• Progenity, Inc.
• Genesis Genetics
• Quest Diagnostics Incorporated

第16章 戦略的提言

第17章 調査会社について・免責事項

The Global Non-invasive Prenatal Testing (NIPT) Market was valued at USD 5.03 billion in 2024 and is projected to reach USD 7.74 billion by 2030, growing at a CAGR of 7.42% during the forecast period. This growth is driven by increased awareness of genetic disorders and the demand for safer, non-invasive prenatal screening alternatives. As maternal age continues to rise globally, so does the risk of chromosomal abnormalities, prompting wider adoption of NIPT as a preferred screening option. The technology offers accurate results using a simple blood sample from the mother, eliminating risks associated with invasive procedures like amniocentesis. Government support for early diagnostic initiatives, advancements in private healthcare access, and the convenience of rapid results further bolster the market. Additionally, innovations such as AI-based analysis and multiplex assay development are broadening the scope and precision of NIPT, while consumer demand for home-based testing solutions is reshaping delivery models to become more patient-centric.

Key Market Drivers

Rising Maternal Age and Associated Risk of Chromosomal Abnormalities

The trend of delayed motherhood, particularly across Europe, is fueling demand for NIPT. As women increasingly postpone childbirth for career or financial reasons, the average maternal age continues to climb-reaching 30.9 years in England and Wales in 2023, according to the ONS. This age shift is associated with heightened risk for chromosomal anomalies like Down syndrome, Edwards syndrome, and Patau syndrome. NIPT has become the preferred screening method due to its high accuracy, non-invasive nature, and safety for both mother and fetus. The growing maternal population over the age of 35 is particularly inclined to choose NIPT over invasive diagnostic tests. The incorporation of NIPT into public healthcare systems such as the NHS has further increased access, supporting its widespread adoption as part of routine prenatal care.

Key Market Challenges

Limitations of NIPT

Despite its advantages, NIPT faces certain limitations that hinder universal adoption. The possibility of false-positive or false-negative results may lead to unnecessary follow-up procedures or missed diagnoses, undermining patient confidence. Since NIPT is a screening-not diagnostic-tool, positive results must be confirmed through invasive testing methods like amniocentesis or CVS, which may deter some from pursuing initial screening. Additionally, NIPT is largely focused on detecting chromosomal abnormalities and may not identify rare or functional genetic disorders, leaving gaps in comprehensive fetal health assessment. Cost also remains a concern, particularly for patients without insurance coverage or in regions where testing is not publicly funded. The lower sensitivity of NIPT for rare conditions and de novo mutations presents further challenges for families seeking exhaustive genetic insights.

Key Market Trends

Availability of Direct-to-Consumer Tests

The emergence of direct-to-consumer (DTC) NIPT is reshaping the market by expanding accessibility and convenience. These at-home testing options enable individuals to initiate genetic screening without visiting a healthcare provider, promoting early decision-making and broader adoption. DTC models align with the broader movement toward personalized and proactive healthcare, offering users greater control over prenatal care choices. They are especially beneficial for individuals in remote or underserved regions who face barriers to in-clinic services. While concerns over result interpretation and medical oversight remain, the convenience and consumer empowerment offered by DTC NIPT options are expected to drive future demand and innovation within the market.

Key Market Players

• YOURGENE HEALTH Plc
• Illumina, Inc.
• Natera, Inc.
• F. Hoffman-La Roche Ltd.
• PerkinElmer Inc.
• Laboratory Corporation of America Holdings
• Eurofins LifeCodexx GmbH
• Progenity, Inc.
• Genesis Genetics
• Quest Diagnostics Incorporated

Report Scope:

In this report, the Global Non-invasive Prenatal Testing (NIPT) Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Non-invasive Prenatal Testing (NIPT) Market, By Product Type:

• Consumables
• Instruments

Non-invasive Prenatal Testing (NIPT) Market, By Test Type:

• Materni 21
• Harmony
• Panaroma
• Verifi
• NIFTY
• Others

Non-invasive Prenatal Testing (NIPT) Market, By Method:

• Ultrasound Detection
• Biochemical Screening Testing
• Cell-Free DNA Maternal Plasma Tests
• Fetal Cells in Maternal Blood Tests
• Others

Non-invasive Prenatal Testing (NIPT) Market, By Application:

• Trisomy
• Microdeletion Syndrome
• Others

Non-invasive Prenatal Testing (NIPT) Market, By End User:

• Diagnostic Laboratories
• Hospitals
• Others

Non-invasive Prenatal Testing (NIPT) Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Non-invasive Prenatal Testing (NIPT) Market.

Available Customizations:

Global Non-invasive Prenatal Testing (NIPT) Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validations
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Non-invasive Prenatal Testing (NIPT) Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product Type (Consumables, Instruments)
  • 5.2.2. By Test Type (Materni 21, Harmony, Panaroma, Verifi, NIFTY, Others)
  • 5.2.3. By Method (Ultrasound Detection, Biochemical Screening Testing, Cell-Free DNA Maternal Plasma Tests, Fetal Cells in Maternal Blood Tests, Others)
  • 5.2.4. By Application (Trisomy, Microdeletion Syndrome, Others)
  • 5.2.5. By End User (Diagnostic Laboratories, Hospitals, Others)
  • 5.2.6. By Region
  • 5.2.7. By Company (2024)
• 5.3. Market Map

6. North America Non-invasive Prenatal Testing (NIPT) Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product Type
  • 6.2.2. By Test Type
  • 6.2.3. By Method
  • 6.2.4. By Application
  • 6.2.5. By End User
  • 6.2.6. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Non-invasive Prenatal Testing (NIPT) Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product Type
      • 6.3.1.2.2. By Test Type
      • 6.3.1.2.3. By Method
      • 6.3.1.2.4. By Application
      • 6.3.1.2.5. By End User
  • 6.3.2. Canada Non-invasive Prenatal Testing (NIPT) Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product Type
      • 6.3.2.2.2. By Test Type
      • 6.3.2.2.3. By Method
      • 6.3.2.2.4. By Application
      • 6.3.2.2.5. By End User
  • 6.3.3. Mexico Non-invasive Prenatal Testing (NIPT) Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product Type
      • 6.3.3.2.2. By Test Type
      • 6.3.3.2.3. By Method
      • 6.3.3.2.4. By Application
      • 6.3.3.2.5. By End User

7. Europe Non-invasive Prenatal Testing (NIPT) Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product Type
  • 7.2.2. By Test Type
  • 7.2.3. By Method
  • 7.2.4. By Application
  • 7.2.5. By End User
  • 7.2.6. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Non-invasive Prenatal Testing (NIPT) Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product Type
      • 7.3.1.2.2. By Test Type
      • 7.3.1.2.3. By Method
      • 7.3.1.2.4. By Application
      • 7.3.1.2.5. By End User
  • 7.3.2. United Kingdom Non-invasive Prenatal Testing (NIPT) Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product Type
      • 7.3.2.2.2. By Test Type
      • 7.3.2.2.3. By Method
      • 7.3.2.2.4. By Application
      • 7.3.2.2.5. By End User
  • 7.3.3. Italy Non-invasive Prenatal Testing (NIPT) Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecasty
      • 7.3.3.2.1. By Product Type
      • 7.3.3.2.2. By Test Type
      • 7.3.3.2.3. By Method
      • 7.3.3.2.4. By Application
      • 7.3.3.2.5. By End User
  • 7.3.4. France Non-invasive Prenatal Testing (NIPT) Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product Type
      • 7.3.4.2.2. By Test Type
      • 7.3.4.2.3. By Method
      • 7.3.4.2.4. By Application
      • 7.3.4.2.5. By End User
  • 7.3.5. Spain Non-invasive Prenatal Testing (NIPT) Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product Type
      • 7.3.5.2.2. By Test Type
      • 7.3.5.2.3. By Method
      • 7.3.5.2.4. By Application
      • 7.3.5.2.5. By End User

8. Asia-Pacific Non-invasive Prenatal Testing (NIPT) Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product Type
  • 8.2.2. By Test Type
  • 8.2.3. By Method
  • 8.2.4. By Application
  • 8.2.5. By End User
  • 8.2.6. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Non-invasive Prenatal Testing (NIPT) Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product Type
      • 8.3.1.2.2. By Test Type
      • 8.3.1.2.3. By Method
      • 8.3.1.2.4. By Application
      • 8.3.1.2.5. By End User
  • 8.3.2. India Non-invasive Prenatal Testing (NIPT) Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product Type
      • 8.3.2.2.2. By Test Type
      • 8.3.2.2.3. By Method
      • 8.3.2.2.4. By Application
      • 8.3.2.2.5. By End User
  • 8.3.3. Japan Non-invasive Prenatal Testing (NIPT) Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product Type
      • 8.3.3.2.2. By Test Type
      • 8.3.3.2.3. By Method
      • 8.3.3.2.4. By Application
      • 8.3.3.2.5. By End User
  • 8.3.4. South Korea Non-invasive Prenatal Testing (NIPT) Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product Type
      • 8.3.4.2.2. By Test Type
      • 8.3.4.2.3. By Method
      • 8.3.4.2.4. By Application
      • 8.3.4.2.5. By End User
  • 8.3.5. Australia Non-invasive Prenatal Testing (NIPT) Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product Type
      • 8.3.5.2.2. By Test Type
      • 8.3.5.2.3. By Method
      • 8.3.5.2.4. By Application
      • 8.3.5.2.5. By End User

9. South America Non-invasive Prenatal Testing (NIPT) Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product Type
  • 9.2.2. By Test Type
  • 9.2.3. By Method
  • 9.2.4. By Application
  • 9.2.5. By End User
  • 9.2.6. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Non-invasive Prenatal Testing (NIPT) Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product Type
      • 9.3.1.2.2. By Test Type
      • 9.3.1.2.3. By Method
      • 9.3.1.2.4. By Application
      • 9.3.1.2.5. By End User
  • 9.3.2. Argentina Non-invasive Prenatal Testing (NIPT) Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product Type
      • 9.3.2.2.2. By Test Type
      • 9.3.2.2.3. By Method
      • 9.3.2.2.4. By Application
      • 9.3.2.2.5. By End User
  • 9.3.3. Colombia Non-invasive Prenatal Testing (NIPT) Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product Type
      • 9.3.3.2.2. By Test Type
      • 9.3.3.2.3. By Method
      • 9.3.3.2.4. By Application
      • 9.3.3.2.5. By End User

10. Middle East and Africa Non-invasive Prenatal Testing (NIPT) Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product Type
  • 10.2.2. By Test Type
  • 10.2.3. By Method
  • 10.2.4. By Application
  • 10.2.5. By End User
  • 10.2.6. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Non-invasive Prenatal Testing (NIPT) Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product Type
      • 10.3.1.2.2. By Test Type
      • 10.3.1.2.3. By Method
      • 10.3.1.2.4. By Application
      • 10.3.1.2.5. By End User
  • 10.3.2. Saudi Arabia Non-invasive Prenatal Testing (NIPT) Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product Type
      • 10.3.2.2.2. By Test Type
      • 10.3.2.2.3. By Method
      • 10.3.2.2.4. By Application
      • 10.3.2.2.5. By End User
  • 10.3.3. UAE Non-invasive Prenatal Testing (NIPT) Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product Type
      • 10.3.3.2.2. By Test Type
      • 10.3.3.2.3. By Method
      • 10.3.3.2.4. By Application
      • 10.3.3.2.5. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Development
• 12.2. Mergers & Acquisitions
• 12.3. Product Launches

13. Global Non-invasive Prenatal Testing (NIPT) Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. YOURGENE HEALTH Plc
• 15.2. Illumina, Inc.
• 15.3. Natera, Inc.
• 15.4. F.Hoffman La Roche Ltd.
• 15.5. Perkin Elmer Inc.
• 15.6. Laboratory Corporation of America Holdings
• 15.7. Eurofins LifeCodex GmbH
• 15.8. Progenity, Inc.
• 15.9. Genesis Genetics
• 15.10. Quest Diagnostics Incorporated

16. Strategic Recommendations

17. About Us & Disclaimer